Published in final edited form as:

Antiviral Res. 2013 January ; 97(1): 74–80. doi:10.1016/j.antiviral.2012.10.009.

Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro

Huiguo Lai¹, G. Sridhar Prasad², and Radhakrishnan Padmanabhan^{1,*}

¹Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC 20057

²CalAsia Pharmaceuticals, Inc., 6330 Nancy Ridge Drive, San Diego, CA 92121

Abstract

Four serotypes of Dengue virus (DENV1–4), mosquito-borne members of *Flaviviridae* family cause frequent epidemics causing considerable morbidity and mortality in humans throughout tropical regions of the world. There is no vaccine or antiviral therapeutics available for human use. In a previous study, we reported that compounds containing the 8-hydroxyquinoline (8-HQ) scaffold as inhibitors of West Nile virus serine protease. In this study, we analyzed potencies of some compounds with (8-HQ)-aminobenzothiazole derivatives for inhibition of DENV2 protease *in vitro*. We identified analogs 1–4 with 2-aminobenzothiazole scaffold with submicromolar potencies (IC₅₀) in the *in vitro* protease assays. The kinetic constant (*K_i*) for the most potent 8-HQ-aminobenzothiazoleinhibitor (compound 1) with an IC₅₀ value of 0.91 ± 0.05 μM was determined to be 2.36 ± 0.13 μM. This compound inhibits the DENV2 NS2B/NS3pro by a competitive mode of inhibition.

Keywords

Dengue virus protease inhibitors; molecular modeling; Molegro Virtual Docker; kinetic analysis; competitive mode of inhibition; sub-micromolar IC₅₀

1. Introduction

DENV, a member of mosquito-borne *Flaviviridae* family (Flavivirus genus), causes significant morbidity and mortality (for reviews, see (Gould and Solomon, 2008; Weaver and Barrett, 2004)). DENV virus is the causative agent of dengue fever, dengue hemorrhagic fever, and toxic shock syndrome (Gould and Solomon, 2008). These diseases are prevalent in tropical regions around the world, where the mosquito species, *Aedes aegypti* and *Aedes albopictus* vectors, thrive and infect humans. A total of 50 to 100 million DENV-related infections occur annually worldwide (Gould and Solomon, 2008). Despite the large burden

© 2012 Elsevier B.V. All rights reserved.

*Corresponding Author: R. Padmanabhan, Ph.D., Department of Microbiology and Immunology, Georgetown University Medical Center, 3900 Reservoir Road, Med-Dent Bldg., Room SW309, Washington, DC 20057, Tel. 202-687-2092, Fax. 202-687-1800, rp55@georgetown.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

to human health, basic research into the development of DENV antiviral therapy has been limited. There are currently no vaccines or antiviral therapeutics available for treatment of DENV-infected patients.

DENV encodes a positive-strand RNA of about 11 kb in length with a type 1 cap, m7GpppA(2'-Om) at the 5'-end but lacking a poly(A) tail at the 3' end. RNA genome is translated to a single polypeptide precursor which is processed to produce 10 mature proteins by co- and post-translational processing (Lindenbach and Rice, 2003). The three proteins, the capsid (C), precursor/mature membrane protein (prM/M), and the envelope (E) form the virion; the seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) are expressed in the infected cells and are required for viral replication (for reviews, see (Beasley, 2005; Lindenbach and Rice, 2003).

The two component viral serine protease, NS2B-NS3, plays a crucial role in viral replication as it is required for processing of the polypeptide precursor prior to the assembly of the viral replicase complex (for reviews, see (Padmanabhan and Strongin, 2010; Sampath and Padmanabhan, 2009)). This requirement makes the viral protease as an excellent target for development of antiviral therapeutics. The viral protease cleavage sites have in common a pair of basic amino acids, R and K, followed by G, S, or A at the P1' position (Lindenbach and Rice, 2003). The serine protease catalytic triad is located within the N-terminal 185 amino acids of NS3 protein (Bazan and Fletterick, 1989; Chambers et al., 1990; Preugschat et al., 1990). NS2B is the required cofactor for NS3 protease activity (Chambers et al., 1991; Falgout et al., 1991; Wengler et al., 1991; Zhang et al., 1992). The NS2B is an integral membrane protein in the endoplasmic reticulum (Clum et al., 1997) containing hydrophobic regions flanking a hydrophilic region of ~44 amino acid residues which forms a complex with the NS3 protease domain (Arias et al., 1993; Chambers et al., 1993; Clum et al., 1997; Falgout et al., 1993). Using an *E. coli*-expressed and purified DENV2 NS2B/NS3pro, an *in vitro* protease assay using fluorogenic peptide substrates was established (Yusof et al., 2000) which was further optimized (Li et al., 2005). The crystal structures of the DENV3 NS2B-NS3pro (Noble et al., 2012) or of WNV NS2B-NS3pro in a covalent complex with a tetrapeptide substrate-based inhibitor (Erbel et al., 2006) or in a non-covalent complex with the trypsin inhibitor, aprotinin (Aleshin et al., 2007; Noble et al., 2012) have been solved. Similarly, the crystal structures of DENV2 (Erbel et al., 2006) and DENV1 (Chandramouli et al., 2010) without a substrate-based or aprotinin inhibitor have been solved (Aleshin et al., 2007). These studies provide some information regarding the role of cofactor NS2B peptide in activation of the NS3pro domain.

In a previous study, we reported that compounds containing an 8-HQ scaffold with two aryl substitutions at 7 position of the 8-HQ ring inhibited WNV protease (Mueller et al., 2008). In a subsequent study, a number of 8-HQ derivatives were analyzed against WNV protease (Ezgimen et al., 2012). A structure activity relationship (SAR) was revealed in that study regarding the nature of the aryl substitutions at the 7-position and the 8-HQ ring substitutions. The aim of the present study was to select a set of derivatives of 8-HQ scaffold, which exhibited good inhibition of WNV protease, and assay them for their inhibition against the DENV2 NS2B-NS3pro. The 8-HQs with aminothiazole or aminobenzothiazole moiety are shown to inhibit the DENV2 protease and the results are presented. Kinetic analysis was also carried out to determine the mode of inhibition of these compounds which is supported by molecular modeling.

2. Materials and Methods

2.1 Materials

The DENV2 NS2B-NS3pro expression plasmid encoding the protease precursor used in this study contains the hydrophilic domain of NS2B cofactor (48 amino acids) and the NS3pro domain (185 residues) (Yon et al., 2005). The expression and purification of the protease were as described previously (Mueller et al., 2007; Yusof et al., 2000). The fluorogenic peptide substrate, Benzoyl (Bz)-norleucine (Nle)-Lys-Arg-Arg-AMC was purchased from Bachem (Torrance, CA). For later experiments, Bz-Nle-Lys-Arg-Arg-AMC was custom-synthesized by NeoBioScience (Cambridge, MA). AMC was purchased from Anaspec, Inc (Fremont, CA). The sources of compounds 13, 20 and 22 (Fig. 1B) are described in (Ezgimen et al., 2012). Compound **1** (M.W. 489.59) is a new compound synthesized in the laboratory using the previously reported method (Phillips et al., 1953) and the structure was confirmed by NMR. The sources of the compounds **2** (M.W. 439.53; II-11-1), **3** (M.W. 438.54; II-11-6), **4** (M.W. 489.59; II-11-5) were the same as compounds **14**, **18**, and **17** previously described (Ezgimen et al., 2012)).

2.2. *In vitro* DENV2 protease assays

Compounds were analyzed by *in vitro* protease assays performed in opaque 96-well plates. Standard reaction mixture (100 μ l) containing 200 mM Tris-HCl (pH 9.5), 6 mM NaCl, 30 % glycerol, 25 nM DENV2 protease (25 nM), 10 μ M or 25 μ M inhibitors (dissolved in DMSO) were incubated 15 min at 25 °C. Reactions were started by the addition of 5.0 μ M *tetra*-peptide substrate, (Bz)-Nle-Gly-Arg-Arg-AMC.

Release of free AMC was measured using a spectrofluorometer (Molecular Devices) at excitation and emission wavelengths of 380 and 460 nm, respectively. Fluorescence values obtained with the no-inhibitor control were taken as 100%, and those in the presence of inhibitors were calculated as the percentage of inhibition of the control using Microsoft Excel and plotted using SigmaPlot 2001 v7.0 software. The background of AMC in the absence of protease was subtracted before the data analysis. All assays were performed in triplicate and repeated twice.

2.3. Determination of IC₅₀

To determine the 50% inhibitory concentration (IC₅₀) of a compound, protease assays were performed as described above except in the presence of various concentrations of an inhibitor (0.005 – 50 μ M), which is dissolved in 100% DMSO and the stock concentration is 5.0 mM. All the final DMSO concentration was less than 2% in each well. The IC₅₀ values against DENV2 protease were determined in a buffer containing 200 mM Tris-HCl (pH 9.5), 6 mM NaCl, 30 % glycerol and 0.1% CHAPS. In our assay, CHAPS detergent was included in the assay buffer to eliminate aggregation-based inhibition by a compound (Feng et al., 2007). Fourteen data points were obtained for inhibitor concentrations in the range of 5 nM, 10 nM, 50 nM, 0.1, 0.5, 1, 2, 4, 6, 8, 10, 20, 25, and 50 μ M of selected compounds. IC₅₀ values were calculated using the SigmaPlot 2001 v7.0 software.

2.4. Steady-state kinetic analysis

To determine the K_m and V_{max} values of compound **1**, four different concentrations of each inhibitor (0 to 5 μ M) were assayed at twelve *tetra*-peptide substrate concentrations ranging from 0 – 50 μ M. K_i value was calculated from the secondary plot of obtained K_m (app) against the concentration of inhibitors.

2.5. Molecular docking of compounds 1, 2, 3, and 4 into DENV3 protease

For molecular docking of the compounds 1–4 into the NS2B-NS3pro, we used the crystal structure of DENV3 pro in complex with a peptide based inhibitor (benzoyl-norleucine-Lys-Arg-Arg-H) that was solved to 2.3 Å resolution (PDB ID: 3U1I) (Noble et al., 2012). In the presence of the peptide substrate-based inhibitor, the DENV3 protease adopts a catalytically active closed conformation in which the hydrophilic beta-hairpin region wraps around the NS3 protease domain (Noble et al., 2012). For molecular docking we used Molegro virtual docker, which has been developed recently and gained significant attention among scientists in the field of structure based drug discovery (Thomsen and Christensen, 2006). The small molecule inhibitors were prepared and optimized using ACD software, ChemsSketch. In addition, for consistency, the ligand parameters were also energy minimized using the ligand descriptor option in Molegro. All the water and ligand molecules were deleted from the DENV3 NS2B-NS3pro structure. Hydrogen atoms were added and atomic charges assigned using the protein molecular preparation option in Molegro. Prior to calculating the binding cavities, the side chain conformation of the amino acid residues were minimized globally. We used a grid resolution of 0.5 Å to calculate the cavities in the protein. For docking, a grid resolution of 0.20 Å and a radius of 15 Å around the binding site were used. We used the MolDock optimizer as a search algorithm, and the number of runs was set to 20. A population size of 50, maximum iteration of 1500, scaling factor of 0.50, crossover rate of 0.90 and a variation-based termination scheme for parameter settings were used. The maximum number of poses to generate was set to default value of 5. The solution corresponding to top ranked score from each run was used to create the resulting docked protein:ligand complex structure.

3. Results and Discussion

3.1. Inhibition of DENV2 NS2B/NS3pro by 8-HQ-aminobenzothiazole derivatives

In our previous study, we reported identification of small molecule inhibitors of WNV NS2B-NS3pro using a fluorogenic tripeptide substrate, Boc-G-K-R-AMC, in a HTS campaign. The 98 compounds selected as primary “hits” with drug-like physicochemical and pharmacological properties were divided into five groups based on structural similarity. Two groups of compounds are 8-HQ derivatives with substitutions at 7- position that are linked to either an —NH—C=O or an —NH— group (Mueller et al., 2008). The lead compound (Compound **B**) is an 8-HQ derivative belonging to the —NH— group (structure similar to compound **24** in Fig. 1B except with a —OH group in the *ortho* position), was reported to have a K_i value of $3.4 \pm 0.6 \mu\text{M}$ (Mueller et al., 2008). In a recent study, sixteen 8-HQ derivatives (including the lead compound **B** used as a control) with a general structure shown in Fig. 1A with different **R2** and **R3** aryl substitutions were analyzed against West Nile virus NS2B-NS3pro (Ezgimen et al., 2012) using a tripeptide substrate, Boc-G-K-R-AMC. It is noteworthy that the K_m of the WNV protease for the tripeptide (Boc-G-K-R-AMC) substrate was reported as $737 \pm 150 \mu\text{M}$ (Mueller et al., 2007) whereas with the tetrapeptide substrate, Bz-Nle-Lys-Arg-Arg-AMC, the K_m was $24.56 \pm 1.43 \mu\text{M}$. Therefore, in this study, the in vitro assays for WNV and DENV2 proteases were performed using the tetra-peptide substrate which was found to be the optimum substrate for the DENV2 protease (Li et al., 2005).

Of the 16 derivatives of 8-HQ scaffold tested, 9 compounds showed inhibitory activity of >95% whereas among the other seven, the % inhibition were in the range of 20–80%. Fourteen out of 16 compounds had either aminothiazole or benzaminothiazole ring as **R3** substitution and phenylmethyl, phenolic hydroxyl, or benzyloxy phenyl as **R2** substitution (Fig. 1A). A rational structure activity relationship (SAR) was revealed. Importantly, it was revealed that the N at 1- position of the 8-HQ ring was shown to be essential for inhibition

of the WNV protease because substitution of 8-hydroxyquinoline ring with a naphthalen-1-ol ring (N replaced with —CH—), reduced the inhibitory activity by ~75% (dropped from ~99% to 26%). In this study, we analyzed seven compounds including one novel compound (compound **1**) synthesized for this study (Fig. 1B and 1C) for their inhibition of DENV2 NS2B/NS3pro. All have aryl substitutions at 7- position with a thiazole or a benzothiazole moiety as an **R3** aryl substitution in the general structure shown in Fig. 1A. The **R2** substitution varied as phenyl, phenylhydroxyl, 2-(benzyloxy)phenyl or 3-(benzyloxy)phenyl moiety (Fig. 1B and 1C).

The *in vitro* protease assays were performed using the DENV2 protease NS2B/NS3-pro in the absence or the presence of an inhibitor compound at a fixed concentration of 10 and 25 μ M and the Bz-Nle-Lys-Arg-Arg-AMC substrate. The inhibitory activities of three compounds (Fig. 1B), **13**, **22**, and **24**, which had 95% inhibition of WNV protease with the tri-peptide substrate (Ezgimen et al., 2012), were in the range of 48–69% at 10 μ M and 60–85% at 25 μ M against the DENV2 NS2B-NS3 protease with the tetra-peptide substrate (Table 1). All four compounds (compounds **1–4** in Fig. 1C) showed good inhibition (79–93%) against DENV2 protease. The activities of the four compounds were compared in the absence and presence of 0.1% CHAPS (Table 2). Meanwhile, the top four compounds **1–4** also showed good inhibition against WNV NS2B-NS3 protease in the presence of 0.1% CHAPS (Table 3). The results reveal that compounds **1** and **2** both having the benzyloxy (-OBn) phenyl moiety in the *meta* position in common (**R2** ring in the general structure shown in Fig. 1A), the benzothiazole moiety (**R3** ring in Fig. 1A) in compound **1** contributed to better inhibition of the protease than the thiazole moiety in compound **2** (Table 2). This difference in potency of compounds **1** and **2** is not significant when compounds **3** and **4** are compared in which the -OBn substitution is in the *ortho* position which could be attributed to steric considerations. Yet, compound **4** is a more potent inhibitor than compound **3** indicating that benzothiazole is again preferred over thiazole moiety as an **R3** ring substitution.

3.2. Determination of IC₅₀ values

Next, the IC₅₀ value was determined for each of the four compounds using concentrations of the inhibitor between 5 nM and 50 μ M in the presence and absence of 0.1% CHAPS (Table 2 and Fig. 2A and 2B, respectively). The RFU values were converted into % inhibition and plotted versus the Log₁₀ of compound concentrations resulting in sigmoid concentration-response curves. The apparent IC₅₀ values for compounds **1**, **2**, **3** and **4** were 0.91 ± 0.02 , 2.93 ± 0.05 , 3.67 ± 0.08 , and 2.34 ± 0.14 μ M, respectively. The results suggest that while all four compounds are good inhibitors of DENV2 NS2B-NS3pro, compound **1** showed the maximum inhibition among the four compounds with an IC₅₀ in the 1 μ M range. Compound **1** was also the best of the four compounds in inhibition of WNV protease in the presence of 0.1% CHAPS (Table 3).

3.3. Kinetics of inhibition of DENV2 NS2B/NS3pro by compound 1

Since compound **1** is the best inhibitor in this series, we sought to analyze the mode of inhibition of the DENV2 NS2B/NS3pro-catalyzed cleavage of the *tetra*-peptide substrate by compound **1** in the presence of 0.1% CHAPS. We performed kinetic analysis to determine the K_m , k_{cat} and V_{max} values in the presence and absence of the inhibitor (compound **1**) at four different concentrations. As shown in Table 4 and Fig. 3, the apparent Michaelis-Menten constants ($K_m(app)$) increased and the k_{cat}/K_m decreased proportional to the increase in inhibitor concentrations in the range of 0, 1.0, 3.0 and 5.0 μ M. The corresponding V_{max} values were essentially the same. The results indicate that compound **1** at increasing concentrations reduces the affinity of the enzyme for the substrate as evident

from the increase of K_m values. The obtained K_i values was $2.36 \pm 0.13 \mu\text{M}$. This type of inhibition is a characteristic feature of a competitive mode of inhibition.

To test whether the 8-HQ moiety of the compound **1** has a potential to bind Zn^{2+} ions and thereby affecting its inhibitory activity or kinetic properties, we performed the steady state kinetic experiments in the presence and absence of $40 \mu\text{M}$ ZnCl_2 . The obtained K_m , k_{cat} and V_{max} values are summarized in Table 4 and plotted as Figure 3. The K_m values of DENV2 protease in the absence and presence of Zn^{2+} are $12.78 \pm 0.49 \mu\text{M}$ and $12.82 \pm 1.14 \mu\text{M}$, respectively. The results suggest that Zn^{2+} ions do not affect DENV2 protease affinity with the corresponding *tetra*-peptide substrate. Meanwhile, the k_{cat} values of DENV2 protease in the absence and presence of Zn^{2+} are 0.0974 ± 0.0014 and $0.1000 \pm 0.0014 \text{ s}^{-1}$, respectively. The results suggest that Zn^{2+} ions do not affect DENV2 protease activity with the corresponding *tetra*-peptide substrate. In the presence of inhibitors, the K_m and k_{cat} values are not affected in the presence of Zn^{2+} ions. The results suggest that the inhibitor **1** binds to the DENV2 protease specifically and the zinc chelation does not affect the binding affinity and activity of the inhibitor **1** against the DENV2 protease.

3.4. Molecular modeling of compounds 1–4 into DENV3 NS2B-NS3pro structure

The primary amino acid sequences of NS2B cofactor peptides and the NS3 protease domains of DENV2 and DENV3 exhibit overall sequence identity of ~73%. Therefore, the availability of crystal structure of the substrate-based inhibitor bound DENV3 NS2B-NS3pro in the biologically active conformation should facilitate lead optimization through SAR. To understand the SAR of the compounds **1–4**, we performed molecular docking using the coordinates of the crystal structure of DENV3 NS2B-NS3pro structure (PDB ID: 3U11) (Noble et al., 2012), the only one available for any DENV serotype in a catalytically active closed conformation in which the hydrophilic beta-hairpin region of NS2B wraps around the NS3 protease core. For molecular docking, we used the software, Molegro virtual docker (Fig. 4A and 4B).

Overall, all the four inhibitors bind into the active site of the NS3pro in the similar location as that of the peptide based inhibitor observed in the crystal structure of the DENV3 NS2B-NS3pro:peptide complex (Fig. 4B and (Noble et al., 2012)). However, there are differences in the mode of binding and interaction of different moieties of the compounds **1–4** with the amino residues belonging to the subsites S1–S4 of DENV2 NS2B-NS3 pro. In detail, the S1 subsite formed by amino acid residues, D129, F130, K131, P132, G133, T134, S135, Y150 and Y161, is occupied by the 8-OH quinoline moiety of compound **1**, aminothiazole of compound **2** and phenylmethyl moiety of compounds **3** and **4**. The S2 subsite (D80, D81, G82, T83 of NS2B and V72, K73, K74, D75 of NS3 pro) is occupied by the phenylmethyl moiety of compounds **1** and **2** but there are no interactions between residues of this subsite and the compounds **3** and **4**. Similarly, there are no interactions between the residues of subsite S3 (M84, R85, I86 of NS2B) and any of the compounds, whereas in the crystal structure of DENV3 NS2B-NS3pro: peptide complex, the S3 subsite is occupied by the side-chain of the Lys residue of the peptide inhibitor (Fig. 4B). The S4 subsite (V154, V155) is occupied by amino-thiazole and amino-benzothiazole of compounds **3** and **4**, respectively.

It is worth noting, given the similarity between the structures of compounds **1** and **2**, and compounds **3** and **4**, compounds **1** and **2** interact with residues of subsites S1 and S2, whereas compounds **3** and **4** interact with subsites S1 and S4. The observed potency $0.91 \pm 0.02 \mu\text{M}$ (Table 2) of compound **1** could be attributed due to the favorable hydrophobic interaction of the bulkier 8-HQ with three aromatic residues F130, Y150 and Y161 of the subsite S1, whereas, in compounds **2** and **3** a relatively smaller aromatic moiety occupies this S1 subsite. Interestingly, compound **4** also contains a bulkier benzothiazole moiety,

however, this moiety occupies the S2 subsite formed by V154 and V155, a small aliphatic side chain residue and is also exposed towards the solvent as compared to the large hydrophobic pocket of S1 subsite occupied by the 8-HQ moiety of compound **1**. The docking of the compounds **1–4** using the catalytically active conformation crystal structure of the NS2B-NS3pro:ligand complex (Fig. 4A) and its comparison to the binding of the peptide based inhibitor bound to NS2B-NS3pro (Fig. 4B) provides valuable information to understand the structure activity relationship of the compounds and ideas to improve the biochemical and cellular potencies for the design and testing for this new class of non-peptide based 8-HQ as DENV protease inhibitors.

Many DENV proteins have been targeted for drug discovery (for a review, see (Noble et al., 2010). Aminothiazole and aminobenzothiazole moieties are core units in several naturally occurring alkaloids or synthetic compounds (Borzilleri et al., 2006; Das et al., 2006). These moieties elicit diverse physiological and chemotherapeutic activities. The interest in these chemical entities stems also from their importance as key intermediates in organic synthesis namely for the construction of various drugs and biologically active compounds. Many aminothiazole and aminobenzothiazole-containing compounds have so far exhibited very promising antiviral (Shipps et al., 2005; Spector et al., 1998), antiprion (Gallardo-Godoy et al., 2011; Ghaemmaghami et al., 2010; Heal et al., 2007), antitumor (Manjula et al., 2009; Oanh et al., 2011), and anticancer (Heiser et al., 2002; Sagi et al., 2005) and other biological properties (Patman et al., 2007; van Muijlwijk-Koezen et al., 2001). The 8-HQ moiety have been found in many drugs and showed broad spectrum of biological activities (Ezgimen et al., 2012; King et al., 2010; Lai et al., 2009; Lu et al., 2006).

In conclusion, our results reveal an inhibitor of DENV2 NS2B-NS3 protease by a compound bearing an 8-HQ scaffold with two aryl substitutions at 7- position, 3-(benzyloxy)phenyl and an amino-benzothiazole with an IC₅₀ value in the 1 μ M range. It inhibits the DENV2 NS2B-NS3 protease by competing with the substrate binding in the vicinity of the active site which is supported by molecular modeling. Further work to solve the co-crystal structure of the protease in complex with the inhibitor is necessary to gain insight into the precise orientation of the compound in the active site.

Acknowledgments

This work was supported in whole or in part, by National Institutes of Health grants, AI070791-03S1, U01-AI082068 and a bridge funding from Biomedical Graduate Research Organization of Georgetown University (to R. P.) and the NIH grant awarded to the New England Regional Center of Excellence (NSRB) (U54 AI057159).

REFERENCES

- Aleshin AE, Shiryayev SA, Strongin AY, Liddington RC. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. *Protein Sci.* 2007; 16:795–806. [PubMed: 17400917]
- Arias CF, Preugschat F, Strauss JH. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. *Virology.* 1993; 193:888–899. [PubMed: 8460492]
- Bazan JF, Fletterick RJ. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. *Virology.* 1989; 171:637–639. [PubMed: 2548336]
- Beasley DW. Recent advances in the molecular biology of west nile virus. *Curr Mol Med.* 2005; 5:835–850. [PubMed: 16375717]
- Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R Sr, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious

- inhibitor of vascular endothelial growth factor receptor-2. *J Med Chem.* 2006; 49:3766–3769. [PubMed: 16789733]
- Chambers TJ, Grakoui A, Rice CM. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. *J Virol.* 1991; 65:6042–6050. [PubMed: 1833562]
- Chambers TJ, Nestorowicz A, Amberg SM, Rice CM. Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. *J Virol.* 1993; 67:6797–6807. [PubMed: 8411382]
- Chambers TJ, Weir RC, Grakoui A, McCourt DW, Bazan JF, Fletterick RJ, Rice CM. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. *Proc Natl Acad Sci U S A.* 1990; 87:8898–8902. [PubMed: 2147282]
- Chandramouli S, Joseph JS, Daudenarde S, Gatchalian J, Cornillez-Ty C, Kuhn P. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. *J Virol.* 2010; 84:3059–3067. [PubMed: 20042502]
- Clum S, Ebner KE, Padmanabhan R. Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3(Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B. *J Biol Chem.* 1997; 272:30715–30723. [PubMed: 9388208]
- Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweiko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. *J Med Chem.* 2006; 49:6819–6832. [PubMed: 17154512]
- Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. *Nat Struct Mol Biol.* 2006; 13:372–373. [PubMed: 16532006]
- Ezgimen M, Lai H, Mueller NH, Lee K, Cuny G, Ostrov DA, Padmanabhan R. Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. *Antiviral Res.* 2012; 94:18–24. [PubMed: 22343093]
- Falgout B, Miller RH, Lai C-J. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: Identification of a domain required for NS2B-NS3 protease activity. *Journal of Virology.* 1993; 67:2034–2042. [PubMed: 8383225]
- Falgout B, Pethel M, Zhang YM, Lai CJ. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. *J Virol.* 1991; 65:2467–2475. [PubMed: 2016768]
- Feng BY, Simeonov A, Jadhav A, Babaoglu K, Inglese J, Shoichet BK, Austin CP. A high-throughput screen for aggregation-based inhibition in a large compound library. *J Med Chem.* 2007; 50:2385–2390. [PubMed: 17447748]
- Gallardo-Godoy A, Gever J, Fife KL, Silber BM, Prusiner SB, Renslo AR. 2-Aminothiazoles as therapeutic leads for prion diseases. *J Med Chem.* 2011; 54:1010–1021. [PubMed: 21247166]
- Ghaemmaghami S, May BC, Renslo AR, Prusiner SB. Discovery of 2-aminothiazoles as potent antiprion compounds. *J Virol.* 2010; 84:3408–3412. [PubMed: 20032192]
- Gould EA, Solomon T. Pathogenic flaviviruses. *Lancet.* 2008; 371:500–509. [PubMed: 18262042]
- Heal W, Thompson MJ, Mutter R, Cope H, Louth JC, Chen B. Library synthesis and screening: 2,4-diphenylthiazoles and 2,4-diphenyloxazoles as potential novel prion disease therapeutics. *J Med Chem.* 2007; 50:1347–1353. [PubMed: 17305326]
- Heiser V, Engemann S, Bocker W, Dunkel I, Boeddrich A, Waelter S, Nordhoff E, Lurz R, Schugardt N, Rautenberg S, Herhaus C, Barnickel G, Bottcher H, Lehrach H, Wanker EE. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. *Proc Natl Acad Sci U S A.* 2002; 99(Suppl 4):16400–16406. [PubMed: 12200548]

- King ON, Li XS, Sakurai M, Kawamura A, Rose NR, Ng SS, Quinn AM, Rai G, Mott BT, Beswick P, Klose RJ, Oppermann U, Jadhav A, Heightman TD, Maloney DJ, Schofield CJ, Simeonov A. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. *PLoS One*. 2010; 5:e15535. [PubMed: 21124847]
- Lai H, Feng M, Roxas-Duncan V, Dakshanamurthy S, Smith LA, Yang DC. Quinololinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition. *Arch Biochem Biophys*. 2009; 491:75–84. [PubMed: 19772855]
- Li J, Lim SP, Beer D, Patel V, Wen D, Tumanut C, Tully DC, Williams JA, Jiricek J, Priestle JP, Harris JL, Vasudevan SG. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. *J Biol Chem*. 2005; 280:28766–28774. [PubMed: 15932883]
- Lindenbach BD, Rice CM. Molecular biology of flaviviruses. *Adv Virus Res*. 2003; 59:23–61. [PubMed: 14696326]
- Lu Y, Nikolovska-Coleska Z, Fang X, Gao W, Shangary S, Qiu S, Qin D, Wang S. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. *J Med Chem*. 2006; 49:3759–3762. [PubMed: 16789731]
- Manjula SN, Malleshappa Noolvi N, Vipani Parihar K, Manohara Reddy SA, Ramani V, Gadad AK, Singh G, Gopalan Kuttu N, Mallikarjuna Rao C. Synthesis and antitumor activity of optically active thiourea and their 2-aminobenzothiazole derivatives: a novel class of anticancer agents. *Eur J Med Chem*. 2009; 44:2923–2929. [PubMed: 19128861]
- Mueller NH, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson TC, Padmanabhan R. Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen. *Antimicrob Agents Chemother*. 2008; 52:3385–3393. [PubMed: 18606844]
- Mueller NH, Yon C, Ganesh VK, Padmanabhan R. Characterization of the West Nile virus protease substrate specificity and inhibitors. *Int J Biochem Cell Biol*. 2007; 39:606–614. [PubMed: 17188926]
- Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY. Strategies for development of Dengue virus inhibitors. *Antiviral Res*. 2010; 85:450–462. [PubMed: 20060421]
- Noble CG, Seh CC, Chao AT, Shi PY. Ligand-bound structures of the dengue virus protease reveal the active conformation. *J Virol*. 2012; 86:438–446. [PubMed: 22031935]
- Oanh DT, Hai HV, Park SH, Kim HJ, Han BW, Kim HS, Hong JT, Han SB, Hue VT, Nam NH. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents. *Bioorg Med Chem Lett*. 2011; 21:7509–7512. [PubMed: 22036991]
- Padmanabhan, R.; Strongin, AY. Translation and processing of the dengue virus polyprotein. In: Hanley, KA.; Weaver, SC., editors. *Frontiers in Dengue Virus Research*. Norfolk, U.K.: Academic Press; 2010. p. 14-33.
- Patman J, Bhardwaj N, Ramnauth J, Annedi SC, Renton P, Maddaford SP, Rakhit S, Andrews JS. Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. *Bioorg Med Chem Lett*. 2007; 17:2540–2544. [PubMed: 17317165]
- Phillips JP, Keown R, Fernando Q. The reaction of aldehydes and aromatic amines with 8-quinolinol. *J Am Chem. Soc*. 1953; 75:4306–4307.
- Preugschat F, Yao CW, Strauss JH. In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B, and NS3. *J Virol*. 1990; 64:4364–4374. [PubMed: 2143543]
- Sagi K, Fujita K, Sugiki M, Takahashi M, Takehana S, Tashiro K, Kayahara T, Yamanashi M, Fukuda Y, Oono S, Okajima A, Iwata S, Shoji M, Sakurai K. Optimization of a coagulation factor VIIa inhibitor found in factor Xa inhibitor library. *Bioorg Med Chem*. 2005; 13:1487–1496. [PubMed: 15698764]
- Sampath A, Padmanabhan R. Molecular targets for flavivirus drug discovery. *Antiviral Res*. 2009; 81:6–15. [PubMed: 18796313]
- Shipp GW Jr, Deng Y, Wang T, Popovici-Muller J, Curran PJ, Rosner KE, Cooper AB, Girijavallabhan V, Butkiewicz N, Cable M. Aminothiazole inhibitors of HCV RNA polymerase. *Bioorg Med Chem Lett*. 2005; 15:115–119. [PubMed: 15582422]

- Spector FC, Liang L, Giordano H, Sivaraja M, Peterson MG. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. *J Virol.* 1998; 72:6979–6987. [PubMed: 9696789]
- Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. *J Med Chem.* 2006; 49:3315–3321. [PubMed: 16722650]
- van Muijlwijk-Koezen JE, Timmerman H, Vollinga RC, Frijtag von Drabbe Kunzel J, de Groote M, Visser S, AP IJ. Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. *J Med Chem.* 2001; 44:749–762. [PubMed: 11262085]
- Weaver SC, Barrett AD. Transmission cycles, host range, evolution and emergence of arboviral disease. *Nat Rev Microbiol.* 2004; 2:789–801. [PubMed: 15378043]
- Wengler G, Czaya G, Farber PM, Hegemann JH. In vitro synthesis of West Nile virus proteins indicates that the amino-terminal segment of the NS3 protein contains the active centre of the protease which cleaves the viral polyprotein after multiple basic amino acids. *J Gen Virol.* 1991; 72:851–858. [PubMed: 1826736]
- Yon C, Teramoto T, Mueller N, Phelan J, Ganesh VK, Murthy KH, Padmanabhan R. Modulation of the nucleoside triphosphatase/RNA helicase and 5'-RNA triphosphatase activities of dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase. *J Biol Chem.* 2005; 280:27412–27419. [PubMed: 15917225]
- Yusof R, Clum S, Wetzel M, Murthy HM, Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. *J Biol Chem.* 2000; 275:9963–9969. [PubMed: 10744671]
- Zhang L, Mohan PM, Padmanabhan R. Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5. *J Virol.* 1992; 66:7549–7554. [PubMed: 1433530]

- A potent inhibitor of dengue protease with IC_{50} of $0.91 \pm 0.05 \mu M$ has been identified.
- The compound is an 8-hydroxyquinoline containing two aryl substitutions at 7 position.
- Kinetic analysis and molecular modeling support competitive mode of inhibition.

A **B**

C

Fig. 1. Structures of 8-HQ derivatives. **(A)** The general structures of 8-HQ scaffold. **(B)** The structures of 8-HQ scaffold derivatives previously studied against West Nile virus NS2BH-NS3 protease. **(C)** The structures of four compounds that were analyzed in this study are shown.

A.

B. **Fig. 2.**

Determination of IC₅₀ values of inhibitor 1–4 against DENV2 protease in the presence (Fig. 2A) and absence (Fig. 2B) of 0.1% CHAPS. The IC₅₀ values were determined as described under Materials and Methods. The x-values are displayed as the log of compound concentration (0–50 μM). The solid lines are fitted lines using the four-parameter sigmoidal model equation. Inhibitor 1–4 were incubated with DENV2 NS2B/NS3pro (25 nM) in buffer (200 mM Tris-HCl, 6 mM NaCl and 30% glycerol, pH 9.5) for 15 min. Bz-Nle-Lys-Arg-Arg-AMC (5.0 μM) was added to the mixture in a final volume of 100 μL. The fluorescence intensity was measured at 460 nm with excitation at 380 nm and converted to the percentage of protease activity in the absence and presence of inhibitors. The solid line is the theoretical fitting curve based on the Sigmoidal Equation. The apparent IC₅₀ values in the presence of 0.1% CHAPS for compounds 1, 2, 3 and 4 were 0.91 ± 0.02 , 2.93 ± 0.07 , 3.67 ± 0.08 , and 2.34 ± 0.14 μM, respectively. The apparent IC₅₀ values in the absence of 0.1% CHAPS for

compounds **1**, **2**, **3** and **4** were 1.29 ± 0.03 , 2.99 ± 0.06 , 4.88 ± 0.15 , and 3.25 ± 0.12 μM , respectively.

Fig. 3.

Inhibition of DENV2 NS2B/NS3pro protease activity by compound **1**. Initial reaction rates of the *tetra*-peptide substrate (Bz-Nle-Lys-Arg-Arg-AMC) cleavage catalyzed by DENV2 NS2B/NS3pro protease (25 nM) in 200 mM Tris-HCl (pH 9.5), 6.0 mM NaCl, 30% glycerol and 0.1% CHAPS at 37 °C in the presence and absence of 40 μM ZnCl₂ were determined by varying the substrate concentrations in the range of 0, 2, 4, 6, 8, 10, 15, 20, 25, 30, 40 and 50 μM at each concentration of inhibitor fixed at 0 (solid circle), 0 with 40 μM ZnCl₂ (open circle), 1.0 μM (solid triangle) and 1.0 μM with 40 μM ZnCl₂ (open triangle), 3.0 μM (solid square), 3.0 μM and 40 μM ZnCl₂ (open square), 5.0 μM (solid diamond) and 5.0 μM with 40 μM ZnCl₂ (open diamond). The reactions were initiated by the addition of DENV-2 NS2B/NS3pro protease and the fluorescence intensity at 460 nm was monitored with an excitation at 380 nm. Reactions were less than 5% completion in all cases to maintain valid steady-state measurements. The solid lines are fitted lines using the Michaelis-Menten equation. Inset: Secondary plot of K_{m, app} against the concentration of selected compound **1** in the absence of Zn²⁺. Kinetic studies were carried out as described utilizing substrate concentrations of 0–50 μM Bz-Nle-Lys-Arg-Arg-AMC. Each experiment was performed in duplicate and repeated three times. Data were analyzed using SigmaPlot 2001 v7.0 software to determine values for apparent K_m and k_{cat}.

A.

B. **Fig. 4.**

A: Putative binding modes of the docked poses of compounds 1–4 into the binding site of DENV3 NS2B-NS3 protease obtained by computational docking using Molegro virtual docker. Figures 4A and 4B were prepared using PyMol (<http://pymol.sourceforge.net/>). The ligands are shown as ball and stick, the protein is shown as molecular surface and the catalytic triad residues: His51, Asp75 and Ser135 are shown in pink. The sub-sites are labeled as S1, S2, S3, and S4. The S1 subsite is formed by residues D129, F130, K131 (S131), P132, G133, T134, S135, Y150 and Y161; S2 subsite is formed by residues D80 (E81), D81 (D82), G82 (G83), T83 (S84) of NS2B and V72, K73, K74, D75 of NS3 pro; S3 subsite formed by residues M84 (M85), R85 (S86), I86 (I87) of NS2B and S4 subsite formed by V154, V155. Where the corresponding amino acid residues or the numbers are different for DENV2 NS2B-NS3 pro are shown in parentheses.

B. Binding of the benzoyl-norleucine-Lys-Arg-Arg-H into the active site of DENV3 NS2B-NS3 pro as observed in the three-dimensional crystal structure of DENV3 NS2B-NS3 pro:ligand complex (PDB ID: 3U1I). The sub-sites S1 to S4 and the catalytic triad residues are also shown (labeled in Fig. 4A). The peptide is shown as ball and stick and the protein as surface presentation.

Table 1

Percent inhibition of DENV2 NS2B-NS3 protease by compounds containing the 8-HQ scaffold (Fig. 1B) in the presence of 0.1% CHAPS.

Inhibitors	% Inhibition at 10 μ M	% Inhibition at 25 μ M
13	61.45 $\pm$ 1.28	76.69 $\pm$ 1.74
22	69.02 $\pm$ 1.03	84.52 $\pm$ 1.46
24	48.36 $\pm$ 1.69	59.74 $\pm$ 1.13

Table 2

Percent inhibition and IC₅₀ values of compounds **1**, **2**, **3** and **4** against DENV2 NS2B-NS3 protease in the absence (–) and presence (+) of 0.1% CHAPS.

Inhibitors	CHAPS	% Inhibition at 10 μ M	% Inhibition at 25 μ M	IC ₅₀ (μ M)	Hill slope
1	–	84.64 $\pm$ 1.33	90.62 $\pm$ 1.03	1.29 $\pm$ 0.03	1.14 $\pm$ 0.07
	+	87.32 $\pm$ 1.25	96.39 $\pm$ 1.32	0.91 $\pm$ 0.02	1.05 $\pm$ 0.05
2	–	78.46 $\pm$ 1.06	83.43 $\pm$ 1.29	2.99 $\pm$ 0.06	1.21 $\pm$ 0.06
	+	83.57 $\pm$ 1.21	92.92 $\pm$ 1.26	2.93 $\pm$ 0.07	1.27 $\pm$ 0.06
3	–	66.78 $\pm$ 1.24	83.12 $\pm$ 1.54	4.88 $\pm$ 0.15	1.21 $\pm$ 0.11
	+	76.92 $\pm$ 1.52	92.62 $\pm$ 1.47	3.67 $\pm$ 0.08	1.18 $\pm$ 0.05
4	–	72.57 $\pm$ 1.49	85.46 $\pm$ 1.09	3.25 $\pm$ 0.12	1.24 $\pm$ 0.08
	+	82.78 $\pm$ 1.06	91.79 $\pm$ 1.18	2.34 $\pm$ 0.14	1.02 $\pm$ 0.05

Table 3

Percent inhibition and IC₅₀ values of compounds **1**, **2**, **3** and **4** against WNV NS2B-NS3 protease in the presence of 0.1% CHAPS.

Inhibitors	% Inhibition at 10 μ M	% Inhibition at 25 μ M	IC ₅₀ (μ M)	Hill slope
1	81.85 $\pm$ 1.12	96.79 $\pm$ 0.35	2.39 $\pm$ 0.04	1.19 $\pm$ 0.07
2	72.05 $\pm$ 1.38	87.25 $\pm$ 0.89	3.46 $\pm$ 0.06	1.13 $\pm$ 0.06
3	65.77 $\pm$ 1.49	83.11 $\pm$ 1.08	6.95 $\pm$ 0.12	1.19 $\pm$ 0.14
4	70.25 $\pm$ 1.06	83.65 $\pm$ 1.31	5.15 $\pm$ 0.09	1.17 $\pm$ 0.08

Table 4

Kinetic parameters for the *tetra*-peptide substrate and compound **1** against DENV2 NS2BH-NS3pro at 37 °C in the absence (–) and presence (+) of 40 μ M ZnCl₂.

Inhibitors	[Zn ²⁺]	K_m	k_{cat}	k_{cat}/K_m
μM	40 μM	μM	s^{-1}	$M^{-1}s^{-1}$
0	–	12.78 $\pm$ 0.49	0.0974 $\pm$ 0.0014	5082 $\pm$ 271
	+	12.82 $\pm$ 1.14	0.1000 $\pm$ 0.0014	5067 $\pm$ 567
1	–	17.61 $\pm$ 1.38	0.0952 $\pm$ 0.0032	3604 $\pm$ 423
	+	17.23 $\pm$ 0.86	0.0987 $\pm$ 0.0021	3683 $\pm$ 270
3	–	27.54 $\pm$ 1.61	0.0972 $\pm$ 0.0029	2353 $\pm$ 212
	+	26.89 $\pm$ 1.16	0.0956 $\pm$ 0.0022	2409 $\pm$ 159
5	–	40.39 $\pm$ 2.66	0.1071 $\pm$ 0.0041	1767 $\pm$ 189
	+	39.32 $\pm$ 2.92	0.1009 $\pm$ 0.0043	1816 $\pm$ 216